article thumbnail

RNA: The most attractive target in recent viral diseases

Chemical Biology and Drug Design

This up-to-date commentary/perspective article sheds light on the revolutionary approaches designed to target the principal viral weapon “RNA” used by RNA viruses (e.g., the severe acute respiratory syndrome coronavirus 2 “SARS-CoV-2”) to infect humans and spread infections, the genomic RNA strands.

RNA 100
article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. The field is faced with a number of obstacles that require specifically assay technologies to surmount.

RNA 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Discovery Article Competition Winner

Drug Target Review

1 Targets were then further validated by combining testing the most promising drug candidates and knocking down specific targets using short interfering RNA (siRNA) and antisense oligonucleotides (ASOs). We can test their viability in the population, speeding up discovery and saving resources associated with laboratory target validation.

Drugs 105
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

This article outlines the various stages of such a workflow, from hypothesis generation to data cleaning and interpretation, referencing the project workflow diagram (Figure 1). At the heart of any research is the scientific question.

RNA 52
article thumbnail

Molecules on the Move: Reversible BTKi in MS, THR-beta Agonist in NASH, and More

Drug Hunter

This article compiles recent high-profile clinical readouts and related news with small molecules of general interest and structures where they are available. Unlike sapropterin, sepiapterin is more active in cells and is also brain-penetrant.

article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

This second ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).

RNA 59
article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA. Today, we are pleased to announce that our article describing one such platform: “ PEARL-seq, A Photoaffinity Platform for the Analysis of Small Molecule-RNA Interactions ” was published in ACS Chemical Biology.

RNA 52